Hybrid AF Therapy | EPi-Sense ST System
The Latest Innovation in Deflection and Control for Epicardial Atrial Fibrillation Ablation for the Treatment of Advanced Afib Patients
The Most Widely Implanted LAAM Device Worldwide
AtriClip devices harness more than 20 years of innovation in Left Atrial Appendage Management (LAAM)
First Patient Treated in LeAAPS Clinical Trial
Safety & effectiveness study to evaluate if prophylactic left atrial appendage exclusion reduces occurrence of ischemic stroke or systemic embolism in cardiac surgery patients with elevated risk of stroke and no history of atrial fibrillation
Find a Specialist
Search for a qualified Hybrid AF Therapy treatment team
First Patient Treated in HEAL-IST™ Trial
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator Synergy Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia
0
Patients Served with Ablation Worldwide
0
AtriClip Devices Sold Worldwide
U.S. NEWS
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
REDUCING GLOBAL AFIB
What is Afib, and how does it affect heart performance?
CAREERS
Interested in joining our mission to reduce the global Afib epidemic?
THERAPY INNOVATION
Post-Operative Pain Management: Opening the Door to Some Cool Options
PM-US-0301K-1225-G
© 2023 Atricure, Inc. All Rights Reserved.
Drs. Peter Tsai and @drdavidsingh from The Queens Medical Center performed their first Hybrid Convergent Procedure! Combining epicardial ablation and endocardial RF ablation, EPs and Cardiac Surgeons are teaming up in the fight against Afib. https://bit.ly/HybridAFTherapy #EPeeps
Drs. Peter Tsai and @drdavidsingh from The Queens Medical Center performed their first Hybrid Convergent Procedure! Combining epicardial ablation and endocardial RF ablation, EPs and Cardiac Surgeons are teaming up in the fight against Afib. https://bit.ly/HybridAFTherapy #EPeeps
LAAM is now a Class 1A recommendation per the 2023 ACC/AHA/ACCP/HRS Guidelines of Diagnosis and Management of #Afib. With 20+ years of innovation and 500,000+ global device implants, we're proud to play a role in advancing Afib treatment. Full guidelines: https://bit.ly/3uCqeAG#LAAM #CardioTwitter
LAAM is now a Class 1A recommendation per the 2023 ACC/AHA/ACCP/HRS Guidelines of Diagnosis and Management of #Afib. With 20+ years of innovation and 500,000+ global device implants, we're proud to play a role in advancing Afib treatment. Full guidelines: https://bit.ly/3uCqeAG#LAAM #CardioTwitter
The Encompass Clamp is the latest RF technology for surgical ablations. We explored its capabilities and how it can aid doctors at #ICC2023. Thanks to those who joined us! To delve deeper into surgical ablations, visit: https://bit.ly/361llVN @ISCAScoronary #CardioTwitter
The Encompass Clamp is the latest RF technology for surgical ablations. We explored its capabilities and how it can aid doctors at #ICC2023. Thanks to those who joined us! To delve deeper into surgical ablations, visit: https://bit.ly/361llVN @ISCAScoronary #CardioTwitter
The 2023 ACC/AHA/ACCP/HRS Guidelines for Diagnosis and Management of #Afib have been released! Left atrial appendage management has been upgraded to Class 1A and Hybrid AF™ Therapy has been added as a Class 2B recommendation. See the full guideline at https://bit.ly/3uCqeAG #LAAM #CardioTwitter #Epeeps
The 2023 ACC/AHA/ACCP/HRS Guidelines for Diagnosis and Management of #Afib have been released! Left atrial appendage management has been upgraded to Class 1A and Hybrid AF™ Therapy has been added as a Class 2B recommendation. See the full guideline at https://bit.ly/3uCqeAG #LAAM #CardioTwitter #Epeeps
social media channels to keep updated on the latest at AtriCure.